E22.2
DESCRIPTION
Patients present with: anorexia, nausea, vomiting, constipation, muscle weakness, myalgia, polyuria, polydipsia, neurologic symptoms (e.g. seizures, coma).
For management see Hyponatraemia.
REFERRAL
Refer to Oncology Unit for management of underlying malignancy producing Antiduretic Hormone (ADH).